Breast Cancer Updates From ESMO 2022
Results from the TROPiCS-02, DATA, GIM2, and METEORA-II trials may help inform the treatment of breast cancer.
Breast Cancer
BREAST CANCER ADVISOR
FEATURED CONTENT
-
-
Cost of Cancer Care Growing for Those With Private Insurance
A team of investigators examined the financial burden of breast, lung, colorectal, and prostate cancers for nonelderly adults with private insurance. -
More Than Half of Oncologists Willing to Reduce Initial Dose in Metastatic Setting
Survey results reveal whether oncologists are willing to adjust initial drug doses for some patients with metastatic cancer. -
Sexual Dysfunction May Be Common Among Women With Cancer
In a cohort of nearly 700 women with cancer, more than 60% reported some type of sexual dysfunction. -
Chemo Does Not Improve Long-Term Outcomes in Early-Stage ILC
Chemotherapy does not improve long-term outcomes in patients with early-stage invasive lobular carcinoma, according to a meta-analysis.
VIDEO SERIES
The Phase 3 PlanB Trial
Continue to Work?
2016 SABCS: Clinical Insights Telli
2016 SABCS: Clinical Insights Oregan
HER2-positive Metastatic and TNBC
Frontline Treatments
Treatment-related Neuropathy
ER-positive, HER2-negative
Emerging Medicines
Triple-negative Breast Cancer
Insights from the Lab and Clinic
Trastuzumab Resistance
Biologic Role of HER2
Strategies in Management
BREAST CANCER NEWS
AEs Related to Antibody-Drug Conjugates Most Common in Breast Cancer
Clinical Trial: Trastuzumab-Based Combinations in HER2+ Breast Cancer
Clinical Trial: Capecitabine Plus Cemiplimab in HR+ Metastatic Breast Cancer
Clinical Trial: Can ctDNA Guide Treatment in High-Risk, ER+/HER2- Breast Cancer?
Clinical Trial: Durvalumab Plus Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Breast Cancer
Loading... 
Loading...